Literature DB >> 11907326

Antigenic sites of foot-and-mouth disease virus (FMDV): an analysis of the specificities of anti-FMDV antibodies after vaccination of naturally susceptible host species.

N Aggarwal1, P V Barnett1.   

Abstract

Of the known neutralizing antigenic sites of foot-and-mouth disease virus (FMDV), site 1 or A, formed in part by the G-H loop of VP1, has historically been considered immunodominant because of evidence implicating its importance in the induction of a protective immune response. However, no systematic study has been done to determine the relative importance of the various specificities of antibodies against the known neutralizing antigenic sites of FMDV in the polyclonal immune response of a natural host after vaccination. In this report, we have adopted a monoclonal antibody-based competition ELISA and used antibodies specific to sites 1, 2 and 3 to provide some insight into this issue. Following vaccination of the three main target species, cattle, pigs and sheep, with an O1 serotype strain, results indicate that none of these three antigenic sites can be considered immunodominant in a polyclonal serum. Interestingly, pigs did not respond to epitopes on the carboxy terminus end of VP1 as efficiently as the ruminant species. In addition to the known sites, other as yet undefined sites might also be important in the induction of a protective immune response. Possible implications for the design of new vaccine strategies for foot-and-mouth disease are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907326     DOI: 10.1099/0022-1317-83-4-775

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

Review 1.  An overview on ELISA techniques for FMD.

Authors:  Li-na Ma; Jie Zhang; Hao-tai Chen; Jian-hua Zhou; Yao-zhong Ding; Yong-sheng Liu
Journal:  Virol J       Date:  2011-09-04       Impact factor: 4.099

2.  Evaluation of genetically engineered derivatives of a Chinese strain of foot-and-mouth disease virus reveals a novel cell-binding site which functions in cell culture and in animals.

Authors:  Qizu Zhao; Juan M Pacheco; Peter W Mason
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Phage Display Screening of Bovine Antibodies to Foot-and-Mouth Disease Virus and Their Application in a Competitive ELISA for Serodiagnosis.

Authors:  Sukyo Jeong; Hyun Joo Ahn; Kyung Jin Min; Jae Won Byun; Hyun Mi Pyo; Mi Young Park; Bok Kyung Ku; Jinju Nah; Soyoon Ryoo; Sung Hwan Wee; Sang Jick Kim
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 4.  How foot-and-mouth disease virus receptor mediates foot-and-mouth disease virus infection.

Authors:  Guangxiang Wang; Yanhua Wang; Youjun Shang; Zhidong Zhang; Xiangtao Liu
Journal:  Virol J       Date:  2015-02-03       Impact factor: 4.099

5.  Unravelling selection shifts among foot-and-mouth disease virus (FMDV) serotypes.

Authors:  Damien C Tully; Mario A Fares
Journal:  Evol Bioinform Online       Date:  2007-02-11       Impact factor: 1.625

6.  Characterization of monoclonal antibodies against foot-and-mouth disease virus serotype O and application in identification of antigenic variation in relation to vaccine strain selection.

Authors:  Ming Yang; Wanhong Xu; Melissa Goolia; Zhidong Zhang
Journal:  Virol J       Date:  2014-08-01       Impact factor: 4.099

7.  Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs.

Authors:  Yimei Cao; Zengjun Lu; Jiachuan Sun; Xingwen Bai; Pu Sun; Huifang Bao; Yingli Chen; Jianhong Guo; Dong Li; Xiangtao Liu; Zaixin Liu
Journal:  Vet Microbiol       Date:  2008-12-11       Impact factor: 3.293

8.  Genetic analysis of foot-and-mouth disease virus serotype A of Indian origin and detection of positive selection and recombination in leader protease-and capsid-coding regions.

Authors:  S B Nagendrakumar; M Madhanmohan; P N Rangarajan; V A Srinivasan
Journal:  J Biosci       Date:  2009-03       Impact factor: 1.826

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.